Veracyte, Inc. (VCYT)’s Insider Jones Evan/ Fa Sold 5,000 Shares; Eventide Asset Management Has Trimmed Its Repligen (RGEN) Holding

Repligen Corporation (NASDAQ:RGEN) Logo

Eventide Asset Management Llc decreased Repligen Corp (RGEN) stake by 29.59% reported in 2019Q3 SEC filing. Eventide Asset Management Llc sold 50,000 shares as Repligen Corp (RGEN)’s stock rose 9.88%. The Eventide Asset Management Llc holds 119,000 shares with $9.13M value, down from 169,000 last quarter. Repligen Corp now has $5.19B valuation. The stock increased 0.22% or $0.22 during the last trading session, reaching $99.6. About 417,324 shares traded or 4.21% up from the average. Repligen Corporation (NASDAQ:RGEN) has risen 46.28% since January 16, 2019 and is uptrending. It has outperformed by 46.28% the S&P500. Some Historical RGEN News: 17/05/2018 – Repligen Forms Golden Cross: Technicals; 17/05/2018 – Repligen to Participate in 15th Annual Craig-Hallum Institutional Investor Conference; 08/05/2018 – REPLIGEN CORP RGEN.O SEES FY 2018 REVENUE $182 MLN TO $188 MLN; 08/05/2018 – REPLIGEN CORP RGEN.O SEES FY 2018 GAAP SHR $0.32 TO $0.36; 08/05/2018 – Repligen Raises FY18 View To EPS 32c-EPS 36c; 17/05/2018 – Repligen Presenting at Conference May 30; 08/05/2018 – Repligen 1Q Adj EPS 17c; 08/05/2018 – Repligen Raises FY18 View To Rev $182M-$188M; 08/05/2018 – Repligen Had Seen FY18 Rev $180M-$186; 08/05/2018 – REPLIGEN FY REV. GUIDANCE RAISED TO $182-$188M, EST. $183.6M

The stock increased 3.05% or $0.87 during the last trading session, reaching $29.44. About 433,424 shares traded. Veracyte, Inc. (NASDAQ:VCYT) has risen 139.77% since January 16, 2019 and is uptrending. It has outperformed by 139.77% the S&P500. Some Historical VCYT News: 22/04/2018 – DJ Veracyte Inc, Inst Holders, 1Q 2018 (VCYT); 23/05/2018 – Veracyte Announces New Study Published in JAMA Surgery Demonstrates Afirma GSC’s Ability to Significantly Reduce Unnecessary; 19/03/2018 – Veracyte Announces New Data Suggesting Afirma GSC’s Ability to Help Significantly More Patients Avoid Unnecessary Thyroid Surgery; 19/05/2018 – Veracyte Announces That Data From Multiple Studies Demonstrate “Real-World” Value of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis; 19/05/2018 – Veracyte: Afirma GSC Identified Significantly More Benign Thyroid Nodules Among Those Deemed Indeterminate; 11/04/2018 – VERACYTE REPORTS PRECISION MEDICINE PACT WITH LOXO ONCOLOGY; 23/05/2018 – Veracyte Announces New Study Published in JAMA Surgery Demonstrates Afirma GSC’s Ability to Significantly Reduce Unnecessary Surgeries in Thyroid Cancer Diagnosis; 19/05/2018 – Veracyte: Data From Studies Show ‘Real-World’ Value of Afirma Genomic Sequencing Classifier in Thyroid Cancer; 23/05/2018 – Veracyte: New Study Shows Afirma GSC’s Ability to Significantly Reduce Unnecessary Surgeries in Thyroid Cancer; 11/04/2018 – VERACYTE INC – FINANCIAL AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED

Investors sentiment decreased to 1.31 in 2019 Q3. Its down 1.15, from 2.46 in 2019Q2. It turned negative, as 30 investors sold Veracyte, Inc. shares while 44 reduced holdings. 35 funds opened positions while 62 raised stakes. 45.46 million shares or 7.85% more from 42.16 million shares in 2019Q2 were reported. C M Bidwell And Associate holds 0.07% of its portfolio in Veracyte, Inc. (NASDAQ:VCYT) for 2,860 shares. Voya Mgmt Limited Liability Company has invested 0% of its portfolio in Veracyte, Inc. (NASDAQ:VCYT). Tower Capital Lc (Trc) invested 0% of its portfolio in Veracyte, Inc. (NASDAQ:VCYT). Affinity Limited holds 0.2% or 26,090 shares in its portfolio. 55,900 are held by Neuberger Berman Grp Ltd Co. Geode Mgmt Lc has 0% invested in Veracyte, Inc. (NASDAQ:VCYT). 693,630 were accumulated by Waddell And Reed Financial. Stifel holds 13,370 shares or 0% of its portfolio. Blair William And Company Il reported 0% of its portfolio in Veracyte, Inc. (NASDAQ:VCYT). Sei Invs Company reported 0% in Veracyte, Inc. (NASDAQ:VCYT). Acuta Partners Ltd Co has 1.95% invested in Veracyte, Inc. (NASDAQ:VCYT) for 112,500 shares. Financial Bank Of America De reported 0% in Veracyte, Inc. (NASDAQ:VCYT). Moreover, Brinker Incorporated has 0.02% invested in Veracyte, Inc. (NASDAQ:VCYT). Kames Capital Public Ltd Co reported 134,331 shares. Credit Suisse Ag, a Switzerland-based fund reported 109,436 shares.

Analysts await Veracyte, Inc. (NASDAQ:VCYT) to report earnings on February, 24. They expect $-0.08 earnings per share, 0.00% or $0.00 from last year’s $-0.08 per share. After $-0.02 actual earnings per share reported by Veracyte, Inc. for the previous quarter, Wall Street now forecasts 300.00% negative EPS growth.

Veracyte, Inc. operates as a molecular diagnostics firm in the United States. The company has market cap of $1.45 billion. The firm uses genomic technology to resolve diagnostic ambiguity. It currently has negative earnings. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

More notable recent Veracyte, Inc. (NASDAQ:VCYT) news were published by: Nasdaq.com which released: “Veracyte (VCYT) Shares Cross Below 200 DMA – Nasdaq” on January 06, 2020, also Seekingalpha.com with their article: “Veracyte collaborates with Acerta Pharma – Seeking Alpha” published on January 08, 2020, Seekingalpha.com published: “Veracyte: Adding Another Big Pharma Partner Backs Bullish Outlook – Seeking Alpha” on January 15, 2020. More interesting news about Veracyte, Inc. (NASDAQ:VCYT) were released by: Nasdaq.com and their article: “Commit To Buy Axon Enterprise At $45, Earn 10% Using Options – Nasdaq” published on January 06, 2020 as well as Finance.Yahoo.com‘s news article titled: “Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma – Yahoo Finance” with publication date: January 08, 2020.

Since August 9, 2019, it had 0 buys, and 3 sales for $1.01 million activity. 15,000 shares were sold by JONES EVAN/ FA, worth $395,681 on Friday, August 9.

As reported in an electronic report that was submitted to the Security and Exchange Commission on January 15, 2020, Jones Evan/ Fa an insider in Veracyte Inc, sold shares worth $142,521 U.S. Dollars in the ‘s company. Jones Evan/ Fa disposed 5,000 new shares, at average $28.5 per share. Jones Evan/ Fa now indirectly has in hand 153702 shares. The insider also directly has in hand 25000 shares. In total it holds a stake of 0.36%.

More notable recent Repligen Corporation (NASDAQ:RGEN) news were published by: Finance.Yahoo.com which released: “Investors Who Bought Repligen (NASDAQ:RGEN) Shares Five Years Ago Are Now Up 289% – Yahoo Finance” on January 10, 2020, also Nasdaq.com with their article: “The 10 Best Healthcare Stocks of the Decade – Nasdaq” published on January 07, 2020, Finance.Yahoo.com published: “The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar’s Opioid Drug – Yahoo Finance” on January 14, 2020. More interesting news about Repligen Corporation (NASDAQ:RGEN) were released by: Seekingalpha.com and their article: “Repligen Gives Investors A Pure Play On Bioproduction – Seeking Alpha” published on January 09, 2020 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance – Benzinga” with publication date: January 15, 2020.

Eventide Asset Management Llc increased Essa Pharma Inc stake by 625,000 shares to 2.01 million valued at $6.44M in 2019Q3. It also upped Nokia Corp (NYSE:NOK) stake by 94,800 shares and now owns 288,800 shares. Myovant Sciences Ltd was raised too.

Among 3 analysts covering Repligen Corporation – Common Stock (NASDAQ:RGEN), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Repligen Corporation – Common Stock has $11000 highest and $100 lowest target. $105’s average target is 5.42% above currents $99.6 stock price. Repligen Corporation – Common Stock had 10 analyst reports since July 22, 2019 according to SRatingsIntel. Leerink Swann initiated the stock with “Buy” rating in Tuesday, October 15 report. The stock of Repligen Corporation (NASDAQ:RGEN) has “Overweight” rating given on Friday, August 23 by Stephens.

Analysts await Repligen Corporation (NASDAQ:RGEN) to report earnings on February, 20. They expect $0.18 earnings per share, down 14.29% or $0.03 from last year’s $0.21 per share. RGEN’s profit will be $9.37M for 138.33 P/E if the $0.18 EPS becomes a reality. After $0.26 actual earnings per share reported by Repligen Corporation for the previous quarter, Wall Street now forecasts -30.77% negative EPS growth.

Veracyte, Inc. (NASDAQ:VCYT) Institutional Positions Chart